Who is sponsoring NCT03393689?

NCT03393689 is sponsored by Rigshospitalet, Denmark.

What drugs are being tested in NCT03393689?

Interventions in NCT03393689: One injection of 68Ga-NODAGA-E[c(RGDyK)]2.

What condition does NCT03393689 study?

NCT03393689 studies Acoustic Neuroma.

Is NCT03393689 still recruiting?

NCT03393689 is currently status unknown. Last updated 10 January 2018.

Last reviewed 2018-01-10 · How we verify

NCT03393689

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

RGD PET/MRI in Sporadic Vestibular Schwannoma

Status unknown Phase 2 Last updated 10 January 2018

What this trial tests

Phase 2 trial testing One injection of 68Ga-NODAGA-E[c(RGDyK)]2 in Acoustic Neuroma in 40 participants. Status unknown.

Timeline

2 January 2018

Primary endpoint
2 January 2021

2 January 2021

Quick facts

Lead sponsor	Rigshospitalet, Denmark
Phase	Phase 2
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	diagnostic
Enrollment	40
Start date	2 January 2018
Primary completion	2 January 2021
Estimated completion	2 January 2021
Sites	1 location across Denmark

Drugs / interventions tested

One injection of 68Ga-NODAGA-E[c(RGDyK)]2 — full drug profile →

Conditions studied

Acoustic Neuroma — all drugs for Acoustic Neuroma →

Sponsor

Rigshospitalet, Denmark

Who can join

Adults 18 to 85, any sex, with Acoustic Neuroma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The aim of this non-randomised, prospective study is to investigate the applicability and prognostic value of angiogenesis PET/MR with the radioligand 68Ga-NODAGA- E\[c(RGDyK)\]2 in patients with sporadic Vestibuarl Schwannomas.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

RGD peptide in cancer targeting: Benefits, challenges, solutions, and possible integrin-RGD interactions.
Javid H, Oryani MA, Rezagholinejad N, Esparham A, et al · · 2024 · cited 137× · PMID 38349028 · DOI 10.1002/cam4.6800
Angiogenesis PET/MRI predicts initial growth of sporadic vestibular schwannomas: a prospective study with follow-up in 29 patients using [<sup>68</sup>Ga]Ga-NODAGA-E[c(RGDyK)]<sub>2</sub>.
Sass HCR, Jensen RG, Johannesen HH, Löfgren JO, et al · · 2026 · PMID 41530428 · DOI 10.1186/s13550-025-01362-z
Angiogenesis PET/MRI predicts initial growth of sporadic vestibular schwannomas: a prospective study with follow-up in 29 patients using [68Ga]Ga-NODAGA-E[c(RGDyK)]2
Sass HC, Jensen RG, Johannesen HH, Löfgren JO, et al · · 2025 · DOI 10.21203/rs.3.rs-7415784/v1

Verify or expand the search:

Other trials of One injection of 68Ga-NODAGA-E[c(RGDyK)]2

Trials testing the same drug.

NCT03271281 — PET/CT Imaging of Angiogenesis in Patients With Neuroendocrine Tumors Using 68Ga-NODAGA-E[c(RGDyK)]2 · Phase 2 · completed

Other recruiting trials for Acoustic Neuroma

Currently open trials in the same condition.

NCT06112509 — Evolution of Vestibular Function After Treatment of a Vestibular Schwannoma by Gamma-knife Radio-surgery · NA · recruiting

Other Rigshospitalet, Denmark trials

Trials by the same sponsor.

NCT07401368 — Clinicians' Trust in AI-Based Fetal Growth Estimates · NA · not yet recruiting
NCT07442357 — The Per-procedural Antibiotic Prophylaxis in Patients Undergoing Transcatheter Aortic Valve Implantation Trial · NA · not yet recruiting
NCT07528729 — Alcohol as a Modifiable Risk Factor for Atrial Fibrillation · NA · not yet recruiting
NCT07511439 — Reversible Effects of Oral Contraceptive Removal on Serotonergic Neurotransmission · Phase 4 · not yet recruiting
NCT07467187 — Invasive Home Ventilation in Denmark · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03393689 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Rigshospitalet, Denmark
Last refreshed: 10 January 2018

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03393689.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing